DNAJB7 (also known as MZB1 or ERDJ5) is a member of the DnaJ/Hsp40 family of molecular chaperones. These proteins play crucial roles in protein folding, quality control, and the cellular stress response. In the context of neurodegeneration, DNAJB7 and related Hsp40 family members have attracted attention for their ability to modulate protein aggregation, a hallmark of diseases like [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).
Structure and Function
Protein Domain Architecture
DNAJB7 contains several functional domains characteristic of the Hsp40 family:
...
DNAJB7 Protein
DNAJB7 Protein (DnaJ Heat Shock Protein Family Member B7)
DNAJB7 (also known as MZB1 or ERDJ5) is a member of the DnaJ/Hsp40 family of molecular chaperones. These proteins play crucial roles in protein folding, quality control, and the cellular stress response. In the context of neurodegeneration, DNAJB7 and related Hsp40 family members have attracted attention for their ability to modulate protein aggregation, a hallmark of diseases like [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).
Structure and Function
Protein Domain Architecture
DNAJB7 contains several functional domains characteristic of the Hsp40 family:
N-terminal J domain: Conserved domain that interacts with Hsp70 chaperones and stimulates their ATPase activity
Glycine/phenylalanine (G/F)-rich region: Flexible linker region
C-terminal client-binding domain: Binds to unfolded proteins and facilitates Hsp70-mediated refolding
Cysteine string motif: Present in some DNAJB proteins, involved in protein interactions
Molecular Chaperone Activity
DNAJB7 functions as a co-chaperone by:
Recognizing misfolded proteins: The C-terminal domain binds to hydrophobic regions of unfolded proteins
Recruiting Hsp70: The J domain delivers substrates to Hsp70 family proteins
Stimulating ATP hydrolysis: Hsp70 ATP hydrolysis is stimulated, stabilizing the client protein
Facilitating refolding or degradation: Depending on the cellular context, clients may be refolded or targeted for degradation
Role in Neurodegeneration
Protein Aggregation in Neurodegenerative Diseases
Neurodegenerative diseases are characterized by pathological protein aggregation:
[Amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) in Alzheimer's disease
[Alpha-synuclein](/proteins/alpha-synuclein) in Parkinson's disease
[Huntingtin](/proteins/huntingtin) in Huntington's disease
[TDP-43](/mechanisms/tdp-43-proteinopathy) in ALS and frontotemporal dementia
DNAJB7 may modulate these aggregation processes.
Alzheimer's Disease
In Alzheimer's disease, DNAJB7 may play protective roles:
Amyloid-beta handling: DNAJB7 could potentially interact with [APP](/entities/app-protein) processing intermediates
[Tau](/proteins/tau) quality control: May assist in refolding or clearing hyperphosphorylated tau
ER stress: DNAJB7 localizes to the endoplasmic reticulum, where it may mitigate ER stress
Parkinson's Disease
For Parkinson's disease, DNAJB7 involvement includes:
Alpha-synuclein aggregation: Hsp40 family members can inhibit alpha-synuclein fibrillization
ER stress response: PD is associated with ER stress; DNAJB7 may provide neuroprotection
Protein quality control: Overall enhancement of cellular proteostasis
Mechanism of Neuroprotection
DNAJB7 and related Hsp40 proteins protect [neurons](/entities/neurons) through multiple mechanisms:
Inhibition of aggregation: Direct binding to aggregation-prone proteins prevents fibril formation
Facilitated refolding: Cooperation with Hsp70 refolds misfolded proteins
Targeting for degradation: Delivery of irreversibly damaged proteins to the proteasome or [autophagy](/entities/autophagy) system
Stress granule dynamics: Involvement in stress granule assembly and disassembly
Therapeutic Implications
Hsp70-Hsp40 Modulation
The Hsp70-Hsp40 system is an attractive therapeutic target:
Small molecule activators: Compounds that enhance Hsp40-Hsp70 activity could boost proteostasis
Gene therapy: Overexpression of DNAJB7 or related proteins
Protein-based therapeutics: Recombinant Hsp40 proteins as neuroprotective agents
Challenges
Key challenges remain:
[Blood-brain barrier](/entities/blood-brain-barrier): Therapeutic delivery to the CNS
Specificity: Achieving selective modulation without disrupting normal proteostasis
Dosage: Balancing chaperone activity with potential interference in normal protein function
Clinical Relevance
Genetic Associations
While DNAJB7 genetic variants are not strongly associated with neurodegenerative disease risk, the broader Hsp40 family shows:
DNAJC family: Some DNAJC genes have GWAS hits for PD and AD
Modifying mutations: Rare variants in chaperone genes may modify disease onset or progression
Biomarker Potential
The expression of DNAJB7 and related chaperones may serve as:
[Unknown, Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21776078/)
[Unknown, Shorter J. The mammalian disaggregase Hsp104: An instrument for protein aggregate therapy. EMBO Rep. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21776078/)
[Unknown, Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29339439/)
[Bollinger L, et al., Hsp40 proteins in neurodegenerative diseases. J Mol Neurosci. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32212031/)